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The phosphatase of regenerating liver-1, PRL-1, gene was detected in a screen for foveal cone photoreceptor-associated genes. It encodes a
small protein tyrosine phosphatase that was previously immunolocalized to the photoreceptors in primate retina. Here we report that in cones and
cone-derived cultured cells both PRL-1 activity and PRL-1 gene expression are modulated under oxidative stress. Oxidation reversibly inhibited
the phosphatase activity of PRL-1 due to the formation of an intramolecular disulfide bridge between Cys104 within the active site and another
conserved Cys, Cys49. This modulation was observed in vitro, in cell culture and in isolated retinas exposed to hydrogen peroxide. The same
treatment caused a rapid increase in PRL-1 expression levels in cultured cells which could be blocked by the protein translation inhibitor,
cycloheximide. Increased PRL-1 expression was also observed in living rats subjected to constant light exposure inducing photooxidative stress.
We further demonstrated that both oxidation and overexpression of PRL-1 upon oxidative stress are greatly enhanced by inhibition of the
glutathione system responsible for cellular redox regulation. These findings suggest that PRL-1 is a molecular component of the photoreceptor's
response to oxidative stress acting upstream of the glutathione system.
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acid; NEM, N-ethylmaleimide; BSO, buthionine sulfoximine; OS, outer
segment; PIP3, phosphatidylinositol-3,4,5-triphosphate; GSH, glutathione;
Trx, thioredoxin
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doi:10.1016/j.bbamcr.2007.06.005photoreceptors which are concentrated in the center (macula)
of the primate retina and are responsible for high-acuity vision
[1]. The PRL-1 gene is located on human chromosome 6q12,
within a region known to harbor at least two macular dystrophy
loci [2,3]. The corresponding protein, PRL-1, is localized to the
outer segments of red and green, but not blue, cone photo-
receptors in retina [1].
PRL-1, is a member of a family of non-classical protein
tyrosine phosphatases (PTPs) that also includes PRL-2 and
PRL-3 [4,5]. PRL phosphatases represent a type of small (140
to 180 amino acids), prenylated PTPs [6–8]. The catalytic
domain of PRLs shares similarity with dual-specificity PTP
domains, which in other phosphatases dephosphorylate both
tyrosines and serines/threonines and lack any distinct domains.
PRLs share a high degree (N75%) of amino acid sequence
identity within their family, but there is less than 20% homology
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[8–10]. PRLs can be tethered on the membrane surface via
C-terminal farnesylation [5,7,8]. Outside of the PRL family,
PRL-1 shares the highest homology (∼40%) with the dual-
specificity PTPs, Cdc14p and PTEN [8]. PTEN also functions as
a lipid phosphatase [11]. In spite of these homologies, the dual-
specificity or lipid phosphatase activity of PRL-1 has not been
previously addressed.
PRL-1 is expressed in both proliferating and terminally
differentiated tissues including normal embryo, regenerating
liver, fetal liver, adult gastric epithelium, brain and skeletal
muscle cells [1,12–16]. PRL-1 appears to play a growth-
associated role in regulating cell proliferation, tumorigenesis,
and/or differentiation. It is apparently regulated in a cell cycle-
dependent manner, by interacting with tubulin and modulating
spindle dynamics during mitosis, or with the nuclear transcrip-
tion factor, ATF7, to regulate the mitotic progression [17,18].
Expression of PRL-1 has been shown to be elevated in
proliferating cells and during inflammation [19] and is regulated
by P53 and early growth-response-1 [20,21].
In postmitotic cells, where there is no requirement for cell
division-associated roles, PRL-1 is also expressed at significant
levels but its function(s) is(are) completely unknown. Clues
relating to the function of PRL-1 derive from recent studies
showing that several PTPs can be regulated by oxidative
modulation [10,22–27]. The target of this modulation is the
conserved cysteine (Cys) residue within the catalytic site which
can be oxidized, either reversibly or irreversibly, resulting in the
loss of PTP activity [23,27,28]. This mechanism may compli-
ment the known effect of oxidative stress in which protein
tyrosine phosphorylation is stimulated by exposure to free
radicals (40).
Because there is no mitosis in the mature retina, we focused
our functional studies of PRL-1 in photoreceptors on exploring
its role in oxidative regulation. Even under normal conditions,
the eye is subjected to oxidative stress resulting from normal
light exposure and the high rate of oxidative metabolism in the
retina. Cumulative effects of oxidative stress have been
implicated in a number of retinal pathologies including age-
related macular degeneration and some inherited macular
dystrophies [29–31]. Under oxidative stress, production of
reactive oxygen species may also regulate signal transduction in
photoreceptors by inactivating PTPs that could, in turn, up-
regulate protein phosphorylation.
In the present study, we demonstrate that in photoreceptors
and cultured photoreceptor-derived cells, PRL-1 is indeed
modulated by oxidation caused either by treatment with
hydrogen peroxide (H2O2) or by exposure of living retinas to
oxidative stress associated with continuous illumination. We
confirmed that this modulation is based on a specific reversible
formation of an intramolecular disulfide bridge involving the
catalytic cysteine and accompanied by inactivation of phos-
phatase activity. Furthermore, we revealed two novel aspects of
this regulation. First, the expression level of PRL-1 in the retina
and a photoreceptor-derived cell line increases under oxidative
stress and can be blocked by inhibition of protein translation.
Second, there is a clear linkage between the oxidation status ofPRL-1 and the glutathione (GSH) system, a major redox
(reduction–oxidation) regulation pathway of the cell [32]. The
GSH system is engaged in constant regeneration of oxidized
PRL-1 to the reduced state, which is otherwise very prominent
under stress.
2. Materials and methods
2.1. Isolation of retinal RNA
Human retinal RNA for PRL-1 constructs was isolated from 4 mm trephine
punches of macular retina. Rat retinal RNA for quantitative RT-PCR (qRT-PCR)
was isolated from retinas of control and light-exposed rats. Trizol reagent
(Invitrogen, Carlsbad, CA) was used with glycogen added as a carrier, as
previously described [33]. Following isolation, total RNA was DNase-treated
using DNA-free DNase (Ambion, Austin, TX) and RNAyields were quantified
by fluorescence at 530 nm using RiboGreen (Molecular Probes, Eugene, OR).
First-strand cDNAs were synthesized from the total RNA (1 μg/reaction) with
an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA), as described by the
manufacturer.
2.2. Expression and purification of recombinant PRL-1
Plasmid constructs for expressing recombinant wild type (WT) PRL-1 and
PRL-1 mutants with a C-terminal 6xHis affinity tag were generated. Full-length
human PRL-1 cDNA was amplified by RT-PCR of human retinal cDNA with
PRL-1 primers based on GenBank Accession Number NM 003463 forward
primer, 5′-ATGGCTCGAATGAACCGCCCA-3′ and reverse primer (including
sequence for 6xHis in bold) 5′-TTAGTGGTGATGGTGATGATGTT-
GAATGCAACAGTTGTTTCTATG-3′ and cloned in frame into the prokaryotic
expression vector, pETBlue-1, using a pETBlue-1 AccepTor Vector kit
(Novagen, San Diego, CA) to generate the pETBlue1-hisPRL-1 construct.
Cys104Ser (C104S), Cys49Ser (C49S) and Cys99Ser (C99S) mutants of PRL-1
were generated using the pETBlue1-hisPRL-1 construct as template DNAwith a
Quik-Change™ Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA)
according to the manufacturer's instruction manual. Every expression construct,
including the PRL-1 Cys mutants, was verified by DNA sequencing performed
at the Duke University DNA Analysis Facility.
WT and mutant His-tagged PRL-1 expressing plasmids were transformed
into E. coli Tuner™ (DE3) pLacI cells (Novagen) for protein expression. His-
tagged proteins were purified on ProBond resin (Invitrogen) using non-
denaturing conditions. Briefly, sonicated cell lysates were incubated with
ProBond resin for 2 h at 4 °C. Following incubation, ProBond resins were
washed with 20 mM imidazole and eluted with 250 mM imidazole (pH 8.0)
buffer into 50 mM Tris plus 300 mM NaCl.
2.3. Preparation and purification of PRL-1 antibody
The polyclonal antibody against PRL-1 was generated by immunizing
rabbits with purified recombinant His-tagged PRL-1. Rabbit immunizations
were performed by Rockland Laboratories (Gilbertsville, PA). The anti-PRL-1
antibody was affinity purified from rabbit antiserum using Protein A sepharose
CL-4B (Amersham Bioscience, Piscataway, NJ) and NHS-activated Sepharose 4
Fast Flow (Amersham Bioscience) coupled with purified recombinant His-PRL-
1 protein according to the manufacturer's instructions.
2.4. Phosphatase assays
Phosphatase activity assays were based on assays using the fluorogenic
phosphatase substrate, 6, 8-difluoro-4-methylumbelliferyl phosphate (DiFMUP,
Molecular Probes), a preferred aromatic substrate for PRL-1 [34,35]. Various
concentrations of purified protein were incubated with 50 μM DiFMUP in
50 mM Tris–HCl pH 8.0, 50 mM NaCl, 25 mM 3-4-morpholino propanesul-
phonic acid (MOPS), 1 mMDTTand 0.05% Tween-20 in a 100-μl reaction. The
reaction was incubated at 37 °C for 30 min and fluorometric measurements were
taken at an excitation wavelength of 360 nm and an emission wavelength of
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selective tyrosine phosphatase inhibitor sodium orthovanadate (Na3VO4), a
selective serine/threonine (Ser/Thr) phosphatase inhibitor sodium fluoride (NaF)
or okadaic acid.
Detection of phosphatase specificity was based on assays using the
chemically synthesized phosphopeptides: END(pY)INASL, DADE(pY)
LIPQQG and RRA(pT)VA (Promega, Madison, WI). Purified protein was
incubated with 100 μM phosphopeptides in 50 mM Imidazole–HCl (pH 7.2)
and 2 mM DTT (for phosphotyrosine peptides) or 250 mM Imidazole (pH 7.2),
0.1% β-mercaptoethanol, 1 mM EGTA, 25 mM MgCl2 and 0.5 mg/ml bovine
serum albumin (BSA) (for the phosphoserine peptide) in a 50-μl reaction at a
final concentration of 2 mg/ml. The reaction was incubated at 37 °C for 30 min
followed by incubation with the addition of 50 μl Molybdate Dye/Additive
mixture (provided in kit) at room temperature for 15 min. The phospholipid
phosphatase assays were performed using a Malachite Green phosphatase
assay kit (Echelon Biosciences, San Jose, CA) with a water-soluble D-
myo-phosphatidylinositol 3,4,5-trisphosphate substrate (diC8-PIP3; Echelon
Biosciences). Purified human PTEN protein (Upstate, Charlottesville, VA)
was used as an active phospholipid phosphatase control. Various amounts of
purified protein (100 ng–1000 ng) and 100 ng PTEN were incubated with
200 μM diC8-PIP3 in a phosphate free assay buffer containing 100 mM Tris–
HCl, pH 8.0 and 2 mM DTT in 50 μl reactions in a microplate. The reaction
was incubated at 37 °C for 30 min followed by incubation with 200 μl
malachite green solution for 15 min at room temperature. The release of
phosphate was then measured at an absorbance of 620 nm [36]. The amount
of free phosphate was calculated from the standard curve performed with
standard phosphate solution in each assay.
2.5. In vitro H2O2 oxidation and DTT reduction assays
For oxidation assays with H2O2, purified PRL-1 proteins were freshly
dialyzed into buffer containing 50 mM Bis-Tris, 50 mM Tris, and 100 mM
sodium-acetate, pH 7.0, prior to inactivation with H2O2 [37]. Dialyzed PRL-1
adjusted to a final concentration of 2 mg/ml was incubated in the absence or
presence of 100, 200, 500 μM H2O2 in a total volume of 100 μl for 10 min at
room temperature. The reactions were stopped by adding 12.5 U of catalase
(Sigma, Milwaukee, WI) to consume H2O2 (should consume 200 nmol
H2O2/s). PRL-1 reactions treated with 500 μM H2O2 were further incubated
with 4 mM DTT for 30 min at room temperature. Following treatment, 50 μl
per reaction was used for determining PTP activity. In order to minimize the
impact of natural oxidation to the protein stock, freshly purified and dialyzed
recombinant PRL-1 was used in each assay of enzymatic activity.
2.6. MALDI-TOF mass spectrometry
WT PRL-1 and C104S PRL-1 mutant were separated on a SDS-PAGE under
non-reducing conditions following incubation with or without 1 mM H2O2 at
room temperature for 30 min. The oxidized band and reduced band of each
recombinant PRL-1 were visualized by silver staining. Protein bands of interest
were excised from the gel and subjected to destaining, in-gel tryptic digestion
and peptide extraction using a Mass-Prep digestion robot (Micromass, UK). The
peptides were analyzed by matrix-assisted laser desorption ionization-time of
flight-mass spectrometry (MALDI-TOF-MS) using a Voyager DE-Pro (Applied
Biosystems, Foster City, CA).
2.7. Cell culture and treatments
The mouse cone photoreceptor-derived 661W cells, kindly provided by Dr.
Al-Ubaidi (University of Oklahoma, OK) [38], were grown in DMEM
supplemented with 10% FBS and an antibiotic-antimycotic (Gibco, Carlsbad,
CA). For most assays cultures were seeded in a six-well plate or 35 mm
culture dish at a concentration of 1×105 cells in 2 ml growth media and grown
to 85% to 90% confluence. Cells used for H2O2 oxidation assays were
supplemented with varying concentrations of H2O2 added to the media for
30 min or various durations at 37 °C [39]. For GSH depletion in 661W cells
prior to the exposure to H2O2, 1 mM buthionine sulfoximine (BSO, Sigma), a
specific GSH synthesis inhibitor, was used to treat cells for 17 h before thecells were exposed to H2O2 as indicated. GSH levels were obtained using a
GSH detection Kit from Calbiochem. After treatments with H2O2, cells were
washed twice with 2 ml PBS containing 10 U catalase to consume H2O2 and
then lysed in 100 μl extraction buffer containing 40 mM N-ethylmaleimide
(NEM; Pierce, Rockford, IL; to prevent thiol-disulfide exchange), 100 mM
Tris–HCL, pH 7.5, 2% SDS and 1 mM phenylmethylsulfonyl fluoride (PMSF)
on ice for 5 min. Lysates were collected and briefly sonicated. Protein translation
was inhibited by cycloheximide treatment of 661W cells with 100 μg/ml
cycloheximide (Sigma) for 1 h prior to H2O2 treatment. After exposure to 1 mM
H2O2 for increasing times, the cells were washed and lysed as described above.
2.8. Retina tissue treatment with H2O2
Fresh porcine eyes were obtained from a local abattoir. The anterior segment
including cornea, iris, lens and ciliary body were obliquely dissected out with
scissors; vitreous humor was gently removed. The remaining eyecup with retina
attached was incubated with 10 mM or 100 mMH2O2 in DMEMwithout phenol
red at 37 °C for 30 min [40]. Then the media was removed and the retinas were
rinsed with phosphate buffered saline (PBS). Following washes, the retinas were
removed gently and lysed in buffer containing 40 mM NEM, 50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM PMSF and protease inhibitor
cocktail tablet (Complete, Mini EDTA-free; Roche Diagnostics, Indianapolis,
IN). NEM was added to the lysis buffer in order to alkylate free SH groups thus
protecting them from any further oxidation during tissue processing. Note that in
vivo disulfide bonded cysteines could not be alkylated during the NEM
treatment unless they were initially reduced.
2.9. Animals and light exposure
Adult albino Sprague–Dawley rats (weight 180–200 g) were purchased
from Harlan (Indianapolis, IN). Rats were maintained in accordance with the
Institutional Animal Care and Use Committee at Duke University and the
Association for Research in Vision and Ophthalmology statement for the use
of animals in ophthalmic and vision research. Rats were housed convention-
ally under ambient conditions (12 h dark, 12 h light) and fed standard rat
chow and water ad libitum. Experimental animals were exposed to constant
cool white light (720 lx measured at the level of the cages) for up to 7 days
and either sacrificed immediately following light exposure (between 1 pm and
2 pm to minimize circadian fluctuations in the measurements) or returned to
normal cyclic light for 9 weeks before sacrificing. Eyes were removed and the
anterior segments and lenses were cut away. In the animals analyzed
immediately following constant light exposure, retinas were isolated from the
eyecup and were either lysed in extraction buffer containing 100 mM Tris–
HCl and 2% SDS followed by Western blot analysis or stored in RNAlater
(Ambion) at −20 °C for RNA isolation and qRT-PCR analysis. For animals
returned to cyclic light for 9 weeks, the eyecups were postfixed in a mixture
of 2% glutaraldehyde and 2% paraformaldehyde overnight, followed by
dehydration through a graded series of ethanols. Then the eyecups were
embedded in Spurr's low-viscosity epoxy resin. Semithin (1 μm) sections
were obtained with an ultramicrotome (Leica, Heidelberg, Germany). The
sections were attached to glass slides, stained with methylene blue and cover
slipped for histologic analysis.
2.10. Western blots
Protein concentrations in the samples were determined using a DC Protein
Assay Kit assay (Bio-Rad) with BioRad protein Assay standard II BSA as the
standard. Protein samples were denatured in XT sample buffer (Bio-Rad)
under reducing (boiling for 5 min in Bio-Rad XT reducing agent) or non-
reducing conditions and separated on 12% Bis-Tris gels. Proteins were
transferred to PVDF membranes, blocked in 10% fat-free milk and incubated
with 0.4 μg/ml affinity-purified anti-PRL-1. Blots were incubated with a
peroxidase-conjugated secondary antibody (Jackson lab, Bar Harbor, ME) and
bands were visualized using the ECL Plus chemiluminescent detection kit
(Amersham Bioscience). When needed, blots were reprobed with rabbit anti-
thioredoxin (Abcam, Cambridge, MA), or mouse monoclonal anti-γ-tubulin
(Sigma, Saint Louise, MO).
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Real-time quantitation of PRL-1 mRNA was performed, with intron-
spanning primers, using an iCycler iQ detection system (Bio-Rad, Hercules,
CA) with SYBR Green, as previously described [33,41]. First-strand cDNAs
were synthesized from equal amounts of total RNA (1 μg/reaction) with a cDNA
synthesis kit (iScript) as described by the manufacturer (Bio-Rad). Expression
levels were normalized to the geometric mean of the endogenous references,
γ-tubulin (TUBG1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and ribosomal protein L13a (RPL13A) [42] and calculated by the comparative
threshold cycle (CT) method (2
−ΔΔCT) [43]. PCR primer sequences for each
gene analyzed are available upon request.3. Results
3.1. Protein tyrosine phosphatase specificity of PRL-1
The PTP activity of PRL-1 has been documented in previous
studies [4]. However, a systematic study of its phosphoamino
acid specificity has not yet been reported. Theoretically, PRL-1
could act as a traditional PTP or as a dual-specificity PTP
(which dephosphorylates phospho-tyrosyl, -seryl and -threonyl
residues [44]), because the sequence of its catalytic domain,
VHCVAGLGR, matches either PTP type [45,46]. In order to
systematically address the substrate specificity of PRL-1 in vitro
we expressed recombinant, His-tagged PRL-1 in E. coli. It
showed robust, concentration-dependent phosphatase activity
with the non-peptide, synthetic substrate, DiFMUP (Fig. 1A).
Importantly, a serine substitution of the essential conserved
cysteine, Cys104, within the catalytic motif of PRL-1 [47]
resulted in complete loss of phosphatase activity (Fig. 1A).
Biochemical evidence for the PTP specificity of WT PRL-1 was
obtained using several selective phosphatase inhibitors and
phosphopeptide substrates. The selective tyrosine phosphataseFig. 1. Protein tyrosine phosphatase specificity of recombinant PRL-1. (A) Phosphat
whose reaction product, DiFMU, has an excitation/emission maxima of ∼358/450
enzymes were serially diluted in reaction buffer (25 mM MOPS, 50 mM NaCl, 1
completely abolished. (B) Concentrations of the inhibitors used as indicated on the
shown. (C) Recombinant WT PRL-1, C104S PRL-1 and PTEN were incubated wi
incubation with 200 μl malachite green solution for 15 min at room temperature. Rele
phosphate was calculated from the standard curve derived using phosphate solution s
Amount of enzyme used in the assay are indicated on the x-axis. Results are means
sodium fluoride; OA, okadaic acid.inhibitor, Na3VO4, completely inactivated PRL-1 at concentra-
tions of 0.1 mM, whereas the Ser/Thr phosphatase inhibitors,
NaF and okadaic acid, had no reliable effect (Fig. 1B).
Experiments with phosphopeptides also revealed a strong
PRL-1 preference for phosphotyrosine-containing peptides,
END(pY)INASL and DADE(pY)LIPQQG, whereas no activity
was detected with the phosphothreonine-containing peptide,
RRA(pT)VA (Table 1).
PRL-1 also shares 32% homology with human PTEN, a dual-
specificity PTP known to dephosphorylate phospholipid sub-
strates including phosphatidylinositol-3,4,5-triphosphate (PIP3).
However, direct assays showed very little PRL-1 activity toward
PIP3 under conditions where the same amount of PTEN
hydrolyzed PIP3 at a high rate (Fig. 1C). Together, the ex-
periments in Fig. 1 argue that PRL-1 is a tyrosine phosphatase
with no appreciable phosphoserine/threonine or phospholipid
activity.
3.2. In vitro reversible oxidative inactivation of PRL-1 by H2O2
The Cys within the catalytic site of PTPs (Cys104 in PRL-1)
has a low pKa and is therefore more susceptible to oxidation
[48]. In vitro incubation of purified, recombinant, WT PRL-1
with H2O2 resulted in a concentration-dependent decrease in
phosphatase activity (Fig. 2A). A significant, nearly 70%,
inactivation was observed following a 10-min exposure to
500 μM H2O2 (Fig. 2A). This inactivation was reversible
since the subsequent incubation of PRL-1 with the reducing
agent, DTT (4 mM), resulted in complete restoration of PRL-
1 phosphatase activity (Fig. 2B). Freshly purified, recombi-
nant PRL-1 migrated as a single band in a SDS gel. H2O2
treated PRL-1 migrated as two bands, an effect that is
reversible by addition of DTT (Fig. 2B, top panel).ase activities were measured using the phosphatase substrate, DiFMUP (50 μM)
nm. The starting concentration of recombinant PRL-1 s was 800 μg/ml. The
mM DTT and 0.05% Tween-20). The activity of C104S mutant PRL-1 was
x-axis and activities relative to that in the absence of any inhibitors (100%) are
th 200 μM water-soluble diC8-PIP3 substrate at 37 °C for 30 min followed by
ase of phosphate was measured at an absorbance of 620 nm. The amount of free
tandards. Activities are expressed as nmol of phosphate released per min per mg.
(±SE) from representative experiments. Na3VO4, sodium orthovanadate; NaF,
Table 1
Substrate specificity of PRL-1
Substrate Detectable activity
ENDpYINASL +
DADEpYLIPQQG +
RRA(pT/S)VA −
Phospholipids −
Fig. 3. Intramolecular disulfide bond formation between Cys104 and Cys49.
Recombinant WT and Cys mutant PRL-1 s with or without the presence of
varying concentrations (as indicated) of H2O2 or DTT, were subjected in SDS-
PAGE under nonreducing conditions followed by silver staining. The reduced
and oxidized forms of PRL-1 have different electrophoretic mobilities. Redu-,
reduced; Oxi-, oxidized.
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SDS PAGE analysis of WT PRL-1 under reducing
conditions (4 mM DTT) yielded a single protein band
(Fig. 3, top panel). However, PRL-1 preincubation with
increasing concentrations of H2O2 resulted in the appearance
of a second band with an increased electrophoretic mobility
(Fig. 3). The reversibility of this phenomenon argues that the
second band originates from protein reduction rather than
protein cleavage. A similar mobility shift has previously
been documented as a modification of PTEN and results from a
protein conformation change induced by oxidation of sulfhydryl
groups [39].
We proposed, by analogy, that the oxidized form of PRL-1
migrates faster than the reduced form, putatively due to a more
compact protein structure, as a result of intramolecular
disulfide bonding between cysteines. To test this hypothesis
directly we generated an array of PRL-1 mutants in which
individual cysteine residues were replaced with serines. The
PRL-1 protein contains 6 cysteines. Among these, we focused
on three, Cys49, Cys99 and Cys104, which are conserved inFig. 2. In vitro reversible oxidative inhibition of PRL-1. (A) PRL-1 dialyzed in
buffer containing 50 mM Tris, 50 mM Bis–Tris, 100 mM Na-Acetate (pH 7.0),
adjusted to a final concentration of 2 mg/ml was incubated in the absence or
presence of H2O2 in a total volume of 100 μl for 10 min at room temperature.
The reaction was stopped by adding 12.5 U catalase, and the PRL-1 phosphatase
activity was measured immediately after as described in Materials and methods
using DiFMUP. (B) PRL-1 reactions, partially inactivated by 500 μM H2O2,
were further incubated with 4 mM DTT for 30 min at room temperature.
Remaining PTP activity was assayed with DiFMUP as described for Fig. 1 and
expressed as % activity relative to the untreated control PRL-1. Treated PRL-1
was also shown on silver-stained SDS gel (top panel). Results are means from
three independent experiments.all three members of the PRL family. We tested these
recombinant mutant PRL-1s for their abilities to be modified
by oxidation. Each form of mutant PRL-1 was incubated with
various concentrations of H2O2 followed by gel electrophor-
esis and silver staining (Fig. 3). Unlike WT PRL-1, the C104S
and C49S PRL-1 mutants migrated as single bands following
exposure to H2O2 suggesting that these cysteines could
participate in intramolecular disulfide bonding (Fig. 3). In
contrast, the C99S mutant migrated faster in the presence of
H2O2 and therefore could be oxidized. This excludes this
residue from potential participation in intramolecular disulfide
bonding. Interestingly, the susceptibility of this mutant to
oxidation was higher than that of the WT PRL-1 with nearly
100% of the mutant C99S oxidized with 5 mM H2O2
(compared to ∼ half of WT PRL-1 oxidized, Fig. 3).
Direct evidence that the Cys104 and Cys 49 residues
participate in the oxidation-induced formation of an intramo-
lecular disulfide bridge in PRL-1 were obtained by MALDI-
TOF MS. Purified recombinant PRL-1 was incubated with or
without 1 mM H2O2 and run on a SDS-PAGE under non-
reducing conditions. The bands were trypsin-digested and
analyzed by MALDI-TOF. The active-site peptide containing
Cys104 and another peptide containing Cys49 were reliably
detected in the digest (Table 2).
In the oxidized form of PRL-1 two new peptides were
detected at expected molecular masses of 3183.3762 and
3483.3157. These masses correspond to two predicted peptides
cross-linked by a disulfide bond between Cys104 and Cys49,
respectively (Table 2). These findings confirm interpretation of
the oxidized mobility shifts in the WT PRL-1 as the result of the
formation of a disulfide bond between Cys104 and Cys49. Our
findings corroborate those obtained in 2 recent independent
studies [10,34].
Table 2
MALDI-MS detection of intramolecular disulfide bond formation in oxidized WT PRL-1
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To determine whether the oxidative modulation of PRL-1
also occurs in living cells, we examined whether PRL-1 could
be oxidized in a photoreceptor-derived cell line (661W) or in
porcine retina. Both of these preparations show robust
endogenous expression of PRL-1. The data shown in Fig. 4
indicate that incubation of both preparations with H2O2 causesFig. 4. Oxidative status of PRL-1 in 661W cells (A, B) and porcine retina (C)
exposed to H2O2. (A) Mouse photoreceptor-derived 661W cells were grown to
90% confluence. Cells were either incubated with varying concentrations of
H2O2 (as indicated) for 30 min or (B) incubated with 1 mM H2O2 for varying
times (as indicated). (C) Porcine retinas in eyecups were incubated with
indicated concentrations of H2O2 (added to DMEM) for 30 min. Cell or retinal
lysates were alkylated with 40 mMNEM to prevent disulfide exchange. Proteins
were resolved by SDS-PAGE followed by immunoblot analysis with anti-PRL-1
antibody. Equal sample loading was monitored by reprobing the Western blot
with anti-γ-tubulin antibodies (data not shown).the mobility shift in PRL-1 corresponding to the transition
between its reduced and oxidized forms.
The H2O2 concentration dependence assays conducted with
661W cells (Fig. 4A) showed the oxidized form of PRL-1 is
initially detectable at 0.2 mM H2O2 and becomes predominant
at H2O2 concentrations exceeding 0.5 mM. At these high H2O2
concentrations PRL-1 oxidation is extremely rapid and
complete within 5 min of incubation (Fig. 4B). The amount
of H2O2 required to oxidize endogenous PRL-1 in the retina
was higher (Fig. 4C). This may be due to reduced accessibility
of H2O2 to the photoreceptors in the eyecup preparations used
for these experiments or due to a more robust anti-oxidant
system in situ.
3.5. Glutathione levels alter oxidative status of PRL-1 in 661W
cells
GSH is a major cellular redox regulator. To examine the
potential contribution of GSH to the regulation of PRL-1
oxidation, we depleted GSH in cells using BSO. BSO is a
specific inhibitor of γ-glutamylcysteine synthetase, a key
enzyme in GSH synthesis. Pretreatment of 661W cells with
1 mM BSO for 17 h depleted GSH levels by 75% (data not
shown). In these cells, PRL-1 was oxidized at lower concentra-
tions of H2O2 than untreated cells (Fig. 5). The data in Fig. 5
show that 0.2 mM H2O2 caused only a minor PRL-1 oxidation
in control cells (‘−BSO’ lanes), but a rapidly developing, nearly
complete oxidation in the GSH-depleted cells (‘+BSO’ lanes).
3.6. Oxidative stress increases PRL-1 expression in 661W cells
In addition to oxidative modulation of PRL-1 in 661W cells,
analysis of reduced and oxidized PRL-1 protein levels in Fig.
4A, B revealed that PRL-1 protein levels increased with
increasing H2O2 concentrations and/or incubation times. We
also observed this effect when 661W cells were treated with
lower concentrations of H2O2 (0.2 mM; Fig. 5). Pretreatment
Fig. 5. Time-dependent increase in PRL-1 protein levels in 661W cells exposed
to low concentrations of H2O2. 661W cells without pretreatment (−BSO) or
pretreated with 1 mM BSO (+BSO) for 17 h, were incubated with 0.2 mM H2O2
for the indicated times. Equal amounts of protein from each sample were
separated by SDS-PAGE followed by immunoblot analysis with anti-PRL-1.
Equal sample loading was monitored by reprobing the Western blot with anti-
γ-tubulin antibodies.
Fig. 7. Light microscopy of rat retina following 7 days constant light exposure
(A) Rat retina exposed to 7 days constant light (B) Rat retina exposed for 7 days
to constant light, at 9 weeks after return to normal 12 h cyclic light. RPE, retinal
pigment epithelium; OS, outer segments; ONL, outer nuclear layer of
photoreceptors; INL, inner nuclear layer, D, days. Scale bars equal 20 μm.
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0, +BSO lane). To examine whether this effect required
translation of new protein we treated cells with 100 μg/ml
cycloheximide 1 h prior to treatment with 1 mM H2O2 and
observed that no increase in PRL-1 protein levels were observed
when translation was inhibited (Fig. 6).
3.7. Effect of constant light exposure on PRL-1 in the rat retina
To explore oxidative modulation of PRL-1 in photoreceptors
in vivo, we used an experimental model of oxidative stress
caused by exposing animals to constant light (photooxidative
damage paradigm modified from LaVail et al. [49]). Albino rats
were exposed to constant white light for a period of 0, 2, 5, or
7 days as described in Materials and methods. This did not
cause any noticeable morphological changes in their retinas
immediately following the exposure (Fig. 7A), but resulted in a
near complete loss of photoreceptors 9 weeks later (Fig. 7B).
Following light exposure, PRL-1 mRNA and protein levels
were measured in the retinas. PRL-1 mRNA levels, analyzed by
qRT-PCR, increased at 2, 5 days and 7 days of constant light
exposure to nearly 2.5 times the initial level (Fig. 8A). PRL-1
protein expression levels were queried on Western blots and
were also shown to be increased at each increasing length of
light exposure to approximately the same extent after 7 days of
constant illumination. Interestingly, all the PRL-1 at each time
point was reduced, suggesting that this photooxidative insultFig. 6. Influence of the translation inhibitor cycloheximide (CHX) on the time-
dependent increase in PRL-1 protein levels in 661W cells exposed to H2O2.
661W cells were exposed to 1 mM H2O2 for increasing times. One set of cells
was pretreated with 100 μg/ml CHX for 1 h prior to exposure to H2O2 (+CHX)
and the other set were treated only with the H2O2 (−CHX). Equal amounts of
protein from each well were separated by SDS-PAGE followed by immunoblot
analysis with anti-PRL-1 and equal sample loading was monitored by reprobing
with anti-tubulin antibodies.causes a compensatory increase in protein expression level but
does not saturate its capacity to resist oxidative stress. This
behavior of PRL-1 parallels that of a well-established marker of
oxidative stress, thioredoxin (Trx) [50], which also showed an
increase in expression level after 5 and 7 days of light exposure
(Fig. 8B).
4. Discussion
The central observation obtained in this study is that the
expression level and redox status of the small phosphatase,Fig. 8. Increasing expression of PRL-1 mRNA (A) and protein (B) in rat retinas
due to constant moderate light exposure. Albino rats were exposed to the
constant cool white light for 2, 5 and 7 days. Rats kept in normal cyclic light/
dark served as control animals. (A) Real-time qRT-PCR summaries of PRL-1
gene expression in constant light-exposed retinas (Days 2,5,7) relative to
expression in retina at Day 0 (no constant light) (B) Equal amounts protein
(50 μg) of each retinal lysate was subjected to SDS-PAGE followed by
immunoblot analysis with anti-PRL-1 antibody. Data are representative of three
independent experiments. Trx, thioredoxin; Loading ctrl, non-specific bands on
the same blot used as loading control.
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photoreceptor-derived cells are subjected to oxidative stress.
The potential involvement of PRL-1 in managing the stress
response in these cells will be discussed.
4.1. Reversible redox regulation is a general theme in
modulation of protein tyrosine phosphatase activity
Direct evidence supporting the role of reversible oxidation of
Cys residues has recently been described for the regulation of
several phosphatases that leads to a rapid, reversible, stimulus-
induced inactivation of PTPs [22–27]. The catalytic sites of
PTPs contain a conserved Cys that is directly involved in
catalysis and has a low pKa that is susceptible to oxidation [23].
In the classical PTP, PTP1B, formation of a sulphenyl-amide
bond through the bonding of sulfur on the Cys to the backbone
nitrogen of a neighboring serine was detected following
oxidation [27]. In some non-classical PTPs, including PTEN,
Cdc25 and low molecular weight (LMW) PTPs, oxidation by
H2O2 induced formation of an intramolecular disulfide bond
between the Cys in the catalytic domain and another proximal
Cys [22,37,51]. In general, oxidation of Cys moieties to their
sulfenic acid (Cys-SOH) form is reversible. Therefore,
intramolecular bonding in response to oxidation is thought to
protect the Cys from further irreversible oxidation to a sulfenic
acid (Cys-SO2H) or sulfonic acid (Cys-SO3H) form [23,52].
Our results are in total agreement with two recent in-
dependently conducted studies indicating that PRL-1 oxidation
leads to the formation of a disulfide bridge between the catalytic
Cys104 and Cys49 [10,34]. This reaction completely abolishes
PRL-1 catalytic activity and could be reversed by reducing
agents. We complimented in vitro studies of PRL-1 oxidative
modulation with the demonstration that PRL-1 naturally
expressed in cone photoreceptor-derived 661W cells could
also be oxidized (Fig. 4A). Interestingly, this novel result
indicates that the Cys99 moiety also modulates the oxidation of
the catalytic Cys104. Substitution of Cys99 to Ser resulted in
higher sensitivity to the H2O2-induced oxidation in vitro than
WT PRL-1, suggesting that Cys99 can facilitate intramolecular
disulfide bond formation (Fig. 3). Based on the crystal structure
of PRL-1 the Cys99 residue is in close proximity to the C104
residue [10], raising the possibility that the change in the PRL-1
protein conformation induced by the C99S mutation is close
enough to influence the disulfide bonding between C104 and
C49.
4.2. Potential connection between PRL-1 oxidation and the
glutathione cellular redox system
The ability of endogenous PRL-1 to undergo redox
modulation in 661W cells enabled us to test the connection
between this phenomenon and the function of the glutathione
(GSH) system, the major determinant of the cellular redox status
of protein thiols [32,53]. GSH is the non-protein thiol present in
highest concentrations in the cell where it acts as an antioxidant,
as a free radical scavenger, protecting protein sulfhydryls.
Previous reports indicate that other non-classical PTPs, such asLMW-PTP, can be reactivated by the GSH system after being
subjected to exogenous oxidative stress [54]. We showed that
the GSH system specifically controls the redox state of PRL-1
in living cells by demonstrating that its selective reduction
inhibitor, BSO, dramatically increases PRL-1 oxidation in
661W cells exposed to H2O2. This indicates that GSH acts
downstream of PRL-1 by continuously converting it to its
reduced form. In the absence of GSH the entire pool of PRL-1 is
rapidly transformed into its inactive oxidized form.
Another significant result obtained in the same experiment is
that treatment of 661W cells with BSO resulted in a rapid
increase in the PRL-1 expression level (Fig. 5). This suggests
that PRL-1 is an early component of the cellular response to
oxidative stress and in the absence of the normal homeostatic
regeneration by the GSH system the cell acts to replenish the
pool of its reduced form by rapid biosynthesis. This is further
supported by the results in Fig. 6 showing that the increase in
PRL-1 observed in response to oxidative stress is protein
translation dependent.
4.3. Potential involvement of PRL-1 in defense against
oxidative stress in the retina
Oxidative stress is an established risk factor for various
retinal degenerations, particularly in the region of the macula
where the cone photoreceptors are most densely concentrated
and high acuity vision occurs [55,56]. This susceptibility to
oxidative damage is thought to be due to the high
consumption of oxygen, high content of polyunsaturated
fatty acids, daily turnover of photoreceptor outer segment disc
membranes and continuous light exposure which produces
free radicals [55]. Although oxidative stress in the retina
cannot be quantitatively measured in vivo, enhanced suscept-
ibility to retinal photodynamic injury via oxidative stress is
convincingly established in animal models [57,58]. One such
model is based on exposure of a rodent to constant light of
moderate intensity for a period of several days. Although no
immediate morphological changes are observed during
exposure, severe photoreceptor degeneration takes place
within 2 to 3 months after these animals are returned to
normal cyclic light ([49] and Fig. 7). Photooxidative stress is
thought to be a major contributing factor to this degeneration
because the major redox systems are activated [50,57] and
antioxidants have been used to reduce the damaging effects of
constant light [50,59].
In this model of light damage, both mRNA and protein levels
of PRL-1 increased proportionally to the duration of light
exposure to greater than 2 times the initial level (Fig. 8).
Interestingly, all of the PRL-1 in the retinal lysates obtained
from control and light exposed rats was reduced. This suggests
that with this level of oxidative stress the in vivo cellular
defense mechanisms regulating the redox state of PRL-1,
presumably the GSH system (based on our results obtained in
cell culture), are not overwhelmed. Yet, the cells are still
responding to stress by boosting PRL-1 biosynthesis, so that
retinal levels of both PRL-1 and GSH [50] are increased under
photooxidative stress.
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the putative protective role of PRL-1 is directly based on its
ability to retain its phosphatase activity, or simply its ability to
be oxidized by free radicals formed in the cell under the
conditions of stress. Although the amount of GSH in the cell
overwhelmingly exceeds the amount of PRL-1, the redox
properties of the latter may be such that it is more sensitive to
oxidative changes and therefore PRL-1 may be used by
photoreceptors as the first echelon of defense against oxidative
stress. Understanding the roles of the PRL-1 phosphatase
activity and its ability to undergo reversible redox transforma-
tion in the cellular response to oxidative stress is a clear goal of
future experiments.
In summary, our data support the hypothesis that PRL-1 is a
molecular component of the cone photoreceptor's response to
oxidative stress, which causes PRL-1 oxidation and induces its
expression. Under oxidative stress, production of reactive
oxidation species can act as potential second messengers of
signal transduction in cells, inactivating protein tyrosine
phosphatases that may, in turn, uncouple self-regulatory
mechanisms of protein tyrosine kinases and down-regulating
the protein phosphorylation in photoreceptors. This work
provides novel insights into modulation of PRL-1 in oxidative
stressed retina and photoreceptors, suggesting potential roles of
PRL-1 in photoreceptor cell survival under these conditions.
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